^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

AUR102

i
Other names: AUR102, XL102, AUR-102 , AUR 102
Associations
Trials
Company:
Dr. Reddy’s, Exelixis
Drug class:
CDK7 inhibitor
Associations
Trials
6ms
XL102-101: Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101) (clinicaltrials.gov)
P1, N=52, Terminated, Exelixis | N=373 --> 52 | Trial completion date: Oct 2024 --> May 2024 | Active, not recruiting --> Terminated; Business reasons
Enrollment change • Trial completion date • Trial termination • Combination therapy • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • HR positive • HER-2 negative • PGR positive
|
abiraterone acetate • fulvestrant • prednisone • AUR102
10ms
Enrollment closed
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • HR positive • HER-2 negative • PGR positive
|
abiraterone acetate • fulvestrant • prednisone • AUR102
over1year
Novel covalent CDK7 inhibitor potently induces apoptosis in acute myeloid leukemia and synergizes with Venetoclax. (PubMed, J Exp Clin Cancer Res)
Taken together, XL102 with Venetoclax led to synergistic effects in overcoming resistance and provided a strong rationale for clinical evaluation of XL102 as a single agent and in combination with Venetoclax.
Journal
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • CDK1 (Cyclin-dependent kinase 1)
|
Venclexta (venetoclax) • AUR102
3years
First in human phase 1 dose escalation and expansion study of the safety and pharmacokinetics of the oral CDK7 inhibitor XL102 as a single-agent and in combination therapy in patients with inoperable locally advanced or metastatic solid tumors, including breast cancer (SABCS 2021)
In the dose-escalation stages (modified interval 3+3 design), a maximum tolerated (MTD) and/or recommended XL102 dose (RD) for use alone and in combination therapy with standard dose fulvestrant (HR+BC) or abiraterone/prednisone (mCRPC) will be established in independent strata. Accrual: The study began enrolling patients in February 2021 and is ongoing. Total enrollment estimated to be up to 298 subjects.
Clinical • P1 data • PK/PD data • Combination therapy • IO biomarker
|
CDK7 (Cyclin Dependent Kinase 7)
|
HR positive • CDK7 overexpression
|
abiraterone acetate • fulvestrant • AUR102
almost4years
Clinical • New P1 trial • Combination therapy
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • HR positive • HER-2 negative • PGR positive
|
abiraterone acetate • fulvestrant • prednisone • AUR102